Reata Pharmaceuticals Inc (RETA) SEC Filing 8-K Material Event for the period ending Tuesday, September 25, 2018

Reata Pharmaceuticals Inc

CIK: 1358762 Ticker: RETA

View differences made from one to another to evaluate Reata Pharmaceuticals Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Reata Pharmaceuticals Inc.


Assess how Reata Pharmaceuticals Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Reata Pharmaceuticals Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Reata Pharmaceuticals Inc provided additional information to their SEC Filing as exhibits

Ticker: RETA
CIK: 1358762
Form Type: 8-K Corporate News
Accession Number: 0001564590-18-023539
Submitted to the SEC: Tue Sep 25 2018 7:05:09 AM EST
Accepted by the SEC: Tue Sep 25 2018
Period: Tuesday, September 25, 2018
Industry: Pharmaceutical Preparations
  1. Financial Exhibit
  2. Other Events

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: